Synonyms: compound of formula A [US20220024908A1] | TGRX-326 | TGRX326
Compound class:
Synthetic organic
Comment: The chemical structure for deulorlatinib was obtained from WHO proposed INN list 131 (August 2024). Chemically it is a deuterated analogue of the approved dual ALK/ROS1 inhibitor lorlatinib. Deulorlatinib is claimed in Shenzen Targetrx patent US20220024908A1 [1], and we predict that deulorlatinib is the INN for their lead compound TGRX-326 (based on their disclosed pipeline and a meeting abstract [2]).
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
International Nonproprietary Names ![]() |
|
INN number | INN |
13094 | deulorlatinib |
Synonyms ![]() |
compound of formula A [US20220024908A1] | TGRX-326 | TGRX326 |
Database Links ![]() |
|
CAS Registry No. | 2131126-33-3 (source: WHO INN record) |
GtoPdb PubChem SID | 500839898 |
PubChem CID | 162703963 |
Search Google for chemical match using the InChIKey | IIXWYSCJSQVBQM-LMUHODJSSA-N |
Search Google for chemicals with the same backbone | IIXWYSCJSQVBQM |
Search PubMed clinical trials | deulorlatinib |
Search PubMed titles | deulorlatinib |
Search PubMed titles/abstracts | deulorlatinib |
UniChem Compound Search for chemical match using the InChIKey | IIXWYSCJSQVBQM-LMUHODJSSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | IIXWYSCJSQVBQM-LMUHODJSSA-N |